Volume : 12, Issue : 02, February – 2025
Title:
ADVANCING TOPICAL NSAID THERAPY: FORMULATION AND EVALUATION OF POLYMER-BASED DICLOFENAC SODIUM GELS
Authors :
Pavithra S., Roshini R, Thabasoom E, Nikitha G., Vignesh S, Rushita Minesh Shah, Sridevi M, Sathish.M, Dr.P.Sriramcharan Pitta.
Abstract :
Topical formulations of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Diclofenac Sodium gels, offer targeted pain relief with minimal systemic side effects. Diclofenac Sodium, a potent anti-inflammatory agent, is widely used for managing conditions like osteoarthritis, rheumatoid arthritis, and muscle injuries. However, systemic administration of NSAIDs can lead to adverse effects, prompting the need for effective topical delivery systems. Polymer-based gels have emerged as an effective strategy to enhance the skin penetration and controlled release of Diclofenac Sodium, improving therapeutic efficacy while reducing potential side effects. The formulation of polymer-based Diclofenac Sodium gels involves the use of natural and synthetic polymers that provide desirable viscosity, stability, and sustained drug release. These polymers can also enhance the solubility and penetration of Diclofenac, facilitating its absorption through the skin to the target tissues. Key factors in formulation optimization include drug loading, gel consistency, skin compatibility, and release kinetics. Evaluation of these gels typically involves assessing parameters like pH, viscosity, spread ability, and stability. In clinical settings, polymer-based Diclofenac Sodium gels have shown promise in providing localized relief from pain and inflammation with fewer systemic side effects compared to oral NSAIDs. This approach represents a significant advancement in topical NSAID therapy, offering an effective and safer alternative for pain management.
Keywords: Diclofenac Sodium, Topical NSAID, Polymer-based Gel, Drug Delivery, Pain Relief, Inflammation, Skin Penetration, Controlled Release, Formulation, Evaluation.
Cite This Article:
Please cite this article in press Pitta.Sriramcharan et al., Advancing Topical Nsaid Therapy: Formulation And Evaluation Of Polymer-Based Diclofenac Sodium Gels.,Indo Am. J. P. Sci, 2025; 12 (02).
Number of Downloads : 10
References:
1) Dong, X.D.; Svensson, P.; Cairns, B.E. The analgesic action of topical diclofenac may be mediated through peripheral NMDA receptor antagonism. Pain 2009, 147 (1), 36–45.
2) Yarishkin, O.V.; Hwang, E.M.; Kim, D.; Yoo, J.C.; Kang, S.S.; Kim, D.R.; Shin, J.H.J.; Chung, H.J.; Jeong, H.S.; Kang, D.; Han, J.; Park, J.Y.; Hong, S.G. Diclofenac, a non-steroidal anti-inflammatory drug, inhibits L-type Ca channels in neonatal rat ventricular cardiomyocytes. Korean J. Physiol. Pharmacol. 2009, 13 (6), 437–442.
3) Dehghanyar, P.; Mayer, B.X.; Namiranian, K.; Mascher, H.; Müller, M.; Brunner, M. Topical skin penetration of diclofenac after single- and multiple-dose application. Int. J. Clin. Pharmacol. Ther. 2004, 42 (7), 353–359.
4) Kigasawa, K.; Kajimoto, K.; Watanabe, M.; Kanamura, K.; Saito, A.; Kogure, K. In vivo transdermal delivery of diclofenac by ion-exchange iontophoresis with geraniol. Biol. Pharm. Bull. 2009, 32 (4), 684–687.
5) Savic, S.; Weber, C.; Tamburic, S.; Savic, M.; Müller-Goymann, C. Topical vehicles based on natural surfactant/fatty alcohols mixed emulsifier: The influence of two polyols on the colloidal structure and in vitro/in vivo skin performance. J. Pharm. Sci. 2009, 98 (6), 2073–2090.
6) Kantarci, G.; Ozgüney, I.; Karasulu, H.Y.; Arzık, S.; Güneri, T. Comparison of different water/oil microemulsions containing diclofenac sodium: preparation, characterization, release rate, and skin irritation studies. A.A.P.S. PharmSciTech. 2007, 8 (4), E91.
7) Sanna, V.; Peana, A.T.; Moretti, M.D. Effect of vehicle on diclofenac sodium permeation from new topical formulations: In vitro and in vivo studies. Curr. Drug Deliv. 2009, 6 (1), 93–100.
8) Hui, X.; Hewitt, P.G.; Poblete, N.; Maibach, H.I.; Zev Shainhouse, J.; Wester, R.C.; In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteer. Pharm. Res. 1998, 15 (10), 1589–1595.
9) Kienzler, J.L.; Gold, M.; Nollevaux, F. Systemic bioavailability of topical diclofenac sodium gel 1% vs. oral diclofenac sodium in healthy volunteers. J. Clin. Pharmacol. 2010, 50 (1), 50–61.
10) Brunner, M.; Dehghanyar, P.; Seigfried, B.; Martin, W.; Menke, G.; Müller, M. Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation. Br. J. Clin. Pharmacol. 2005, 60 (5), 573–577.
11) Miyatake, S.; Ichiyama, H.; Kondo, E.; Yasuda, K. Randomized clinical comparisons of diclofenac concentration in the soft tissues and blood plasma between topical and oral applications. Br. J. Clin. Pharmacol. 2009, 67 (1), 125–129.
12) Rojo-Vergara, C.; Lopez-Alarcon, C.; Alvarez-Figueroa, M.J. Transdermal penetration of diclofenac in the presence of AAPH-derived peroxyl radicals. Drug Dev. Ind. Pharm. 2009, 35 (8), 976–980.
13) Magnette, J.L.; Kienzler, J.L.; Sallin, D.; Ménart, C.; Nollevaux, F.; Knops, A. Diclofenac systemic exposure is not increased when topical diclofenac is applied to ultraviolet-induced erythema. Eur. J. Clin. Pharmacol. 2004, 60 (8), 591–594.
14) Dreiser, R.L.; Tisne-Camus, M. DHEP plasters as a topical treatment of knee osteoarthritis—A double-blind placebo-controlled study. Drugs Exp. Clin. Res. 1993, 19 (3), 117–123.
15) Brühlmann P.; Michel B.A. Topical diclofenac patch in patients with knee osteoarthritis: A randomized, double-blind, controlled clinical trial. Clin. Exp. Rheumatol. 2003, 21 (2), 193–198.
16) Grace, D.; Rogers, J.; Skeith, K.; Anderson, K. Topical diclofenac versus placebo: A double blind, randomized clinical trial in patients with osteoarthritis of the knee. J. Rheumatol. 1999, 26 (12), 2659–2663.
17) Niethard, F.U.; Gold, M.S.; Solomon, G.S.; Liu, J.M.; Unkauf, M.; Albrecht, H.H.; Elkik, F.; Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J. Rheumatol. 2005, 32, 2384–2392.
18) Barthel, H.R.; Haselwood, D.; Longley, S. III;; Gold, M.S.; Altman, R.D. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin. Arthritis Rheum. 2009, 39 (3), 203–212.
19) Bookman, A.A.M.; Williams, K.S.A.; Shainhouse, J.Z. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: A randomized controlled trial. CMAJ 2004, 171 (4), 333–338.
20) Roth, S.H.; Shainhouse, J.Z. Efficacy and safety of a topical diclofenac solution (pennsaid) in the treament of primary osteoarthritis of the knee: A randomized, double-blind, vehicle-controlled clinical trial. Arch. Intern. Med. 2004, 164 (18), 2017–2023.
21) Simon, L.S.; Grierson, L.M.; Naseer, Z.; Bookman, A.A.; Zev Shainhouse, J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009, 143 (3), 238–245.
22) Tugwell, P.S.; Wells, G.A.; Shainhouse, J.Z. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. J. Rheumatol. 2004, 31, 2002–2012.
23) Baer, P.A.; Thomas, L.M.; Shainhouse, Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: A randomised controlled, 6 week trial [ISRCTN53366886]. B.M.C. Musculoskelet. Disord. 2005, 6, 44.
24) Brühlmann, P.; de Vathaire, F.; Dreiser, R.L.; Michel, B.A. Short-term treatment with topical diclofenac epolamine plaster in patients with symptomatic knee osteoarthritis: Pooled analysis of two randomised clinical studies. Curr. Med. Res. Opin. 2006, 22 (12), 2429–2438.
25) Lequesne, M.G.; Mery, C.; Samson, M.; Gerard, P. Indexes of severity for osteoarthritis of the hip and knee: Validation-value in comparison with other assessment tests. Scand. J. Rheumatol. 1987, 65, 85–89.
26) Bellamy, N.; Buchann, W.W.; Goldsmith, C.H.; Campbell, J.; Stitt, L.W. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol 1988, 15, 1833–1840.
27) Pham, T.; van der Heijde, D.; Lassere, M.; Altman, R.D.; Anderson, J.J.; Bellamy, N.; Hochberg, M.; Simon, L.; Strand, V.; Woodworth, T.; Dougados, M.; OMERACT-OARSI. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. J. Rheumatol. 2003, 30, 1648–1654.
28) Altman, R.D.; Dreiser, R.L.; Fisher, C.L.; Chase, W.F.; Dreher, D.S.; Zacher, J. Diclofenac sodium gel in patients with primary hand osteoarthritis: A randomized, double-blind, placebo- controlled trial. J. Rheumatol. 2009, 36, 1991–1999.
29) Zacher, J.; Altman, R.; Bellamy, N.; Brühlmann, P.; Da Silva, J.; Huskisson, E.; Taylor, R.S.; Topical diclofenac and its role in pain and inflammation: an evidence-based review. Curr. Med. Res. Opin. 2008, 24 (4), 925–950.
30) Mueller, E.A.; Kirch, W.; Reiter, S. Extent and time course of pain intensity upon treatment with a topical diclofenac sodium patch vs. placebo in acute traumatic injury based on a validated end point: Post hoc analysis of a randomized placebo-controlled trial. Expert Opin. Pharmacother. 2010, 11 (4), 493–498.
31) Hsieh, L.F.; Hong, C.Z.; Chern, S.H.; Chen, C.C. Efficacy and side effects of diclofenac patch in treatment of patients with myofascial pain syndrome of the upper trapezius. J. Pain Symptom. Manage. 2010, 39 (1), 116–125.
32) Zimmerman, J.; Siguencia, J.; Tsvang, E. Upper gastrointestinal hemorrhage associated with cutaneous application of diclofenac gel. Am. J. Gastroenterol. 1995, 90 (11), 2032–2034.
33) Predel, H.G.; Koll, R.; Pabst, H.; Dieter, R.; Gallacchi, G.; Giannetti, B.; Bulitta, M.; Heidecker, J.L.; Mueller, E.A. Diclofenac patch for topical treatment of acute impact injuries: A randomised, double-blind, placebo controlled, multicentre study. Br. J. Sports Med. 2004, 38 (3), 318–323.
34) El-Hadidi, T.; El-Garf, A. Double-blind study comparing the use of Volataren Emulgel vs. regular gel during ultrasonic sessions in the treatment of localized traumatic and rheumatic painful conditions. J. Int. Med. Res. 1991, 19 (3), 219–227.
35) Zochling, J.; Bohl-Bühler, M.H.J.; Baraliakos, X.; Feldtkeller, E.; Braun, J. Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—A population-based survey. Clin. Rheumatol. 2006, 25 (6), 794–800.
36) SRIRAMCHARAN, P. & NATARAJAN, JAWAHAR & RAMAN, RAJESHKUMAR & Gajjela, Nagaraju & JUSTIN, A. & SENTHIL, V.. (2022). A REVIEW ON GREEN-SYNTHESIS OF CERIUM OXIDE NANOPARTICLES: FOCUS ON CENTRAL NERVOUS SYSTEM DISORDERS. International Journal of Applied Pharmaceutics. 94-102. 10.22159/ijap.2022v14i4.44487.
37) Sriramcharan, P., Jawahar, N., Rajeshkumar, R., Arivuselvam, R., Antony, J., Ganganagappa, N., & Venkatachalam, S. (2022). Effects of Cerium Oxide and Selected Heavy Metals on the Induction of Cell Death ViaOxidative Stress-Mediated DNA Damage: doi.org/10.26538/tjnpr/v6i7.11. Tropical Journal of Natural Product Research (TJNPR), 6(7), 1108-1112.